Mitoxantrone in refractory acute leukemia in children: A phase I study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1985-06

AUTHORS

Kenneth A. Starling, Arlynn Faye Mulne, Tribhawan S. Vats, Ingrid Schoch, Gary Dukart

ABSTRACT

Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy. All the children had leukemia which was resistant to conventional therapy and all but one patient had received anthracycline therapy prior to the initiation of this trial. Three patients (two with ANLL, one with ALL) received the drug at a dose of 6 mg/m2/day i.v. for 5 days. Both patients with ANLL achieved partial remissions (PR) (105 and 87 days duration). The child with ALL failed to respond to two courses of the drug, and died of progressive disease 45 days after the institution of therapy. Twenty-one patients (14 with ALL, seven with ANLL) were treated with 8 mg/m2/day i.v. mitoxantrone for 5 days. There were three early deaths (all ALL) which were not felt to be secondary to drug toxicity. Four of the 18 children achieved complete remission (CR) (one ANLL - 35 days; three ALL - 39, 31 and 13 days). One child with ANLL achieved a PR (13 days) and one child with ALL showed improvement in his bone marrow status. Twelve children failed to respond to this therapy. Dose-limiting toxicity was not seen among the patients who received 6 mg/m2/day for 5 days. There were five patients who had mucositis and one patient who had nausea and vomiting among those patients who received 8 mg/m2/day for 5 days.(ABSTRACT TRUNCATED AT 250 WORDS) More... »

PAGES

191-195

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00174169

DOI

http://dx.doi.org/10.1007/bf00174169

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1015026290

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/4019122


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alopecia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anthraquinones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gastric Mucosa", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitoxantrone", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Texas Children's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416975.8", 
          "name": [
            "Hematology-Oncology Section, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, TX, U.S.A."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Starling", 
        "givenName": "Kenneth A.", 
        "id": "sg:person.065570553.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.065570553.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nationwide Children's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.240344.5", 
          "name": [
            "Columbus Children's Hospital, Columbus, OH, U.S.A."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mulne", 
        "givenName": "Arlynn Faye", 
        "id": "sg:person.01361214160.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361214160.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Kansas Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.412016.0", 
          "name": [
            "University of Kansas Medical Center, U.S.A."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vats", 
        "givenName": "Tribhawan S.", 
        "id": "sg:person.014175614647.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014175614647.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Medical Research Division, Lederle Laboratories, American Cyanamid Company, Pearl River, NY, U.S.A."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schoch", 
        "givenName": "Ingrid", 
        "id": "sg:person.01035023643.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035023643.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Medical Research Division, Lederle Laboratories, American Cyanamid Company, Pearl River, NY, U.S.A."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dukart", 
        "givenName": "Gary", 
        "id": "sg:person.01103137043.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103137043.20"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejm197902083000603", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045207745"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm00201a012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055938574"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080245438", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080245575", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082219497", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1985-06", 
    "datePublishedReg": "1985-06-01", 
    "description": "Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy. All the children had leukemia which was resistant to conventional therapy and all but one patient had received anthracycline therapy prior to the initiation of this trial. Three patients (two with ANLL, one with ALL) received the drug at a dose of 6 mg/m2/day i.v. for 5 days. Both patients with ANLL achieved partial remissions (PR) (105 and 87 days duration). The child with ALL failed to respond to two courses of the drug, and died of progressive disease 45 days after the institution of therapy. Twenty-one patients (14 with ALL, seven with ANLL) were treated with 8 mg/m2/day i.v. mitoxantrone for 5 days. There were three early deaths (all ALL) which were not felt to be secondary to drug toxicity. Four of the 18 children achieved complete remission (CR) (one ANLL - 35 days; three ALL - 39, 31 and 13 days). One child with ANLL achieved a PR (13 days) and one child with ALL showed improvement in his bone marrow status. Twelve children failed to respond to this therapy. Dose-limiting toxicity was not seen among the patients who received 6 mg/m2/day for 5 days. There were five patients who had mucositis and one patient who had nausea and vomiting among those patients who received 8 mg/m2/day for 5 days.(ABSTRACT TRUNCATED AT 250 WORDS)", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00174169", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "3"
      }
    ], 
    "name": "Mitoxantrone in refractory acute leukemia in children: A phase I study", 
    "pagination": "191-195", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00174169"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "4796eea39032581385da631fbc2be1b7673226be3b9606094c47202acc3ef7ba"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1015026290"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "4019122"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00174169", 
      "https://app.dimensions.ai/details/publication/pub.1015026290"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T08:49", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000374_0000000374/records_119724_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00174169"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00174169'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00174169'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00174169'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00174169'


 

This table displays all metadata directly associated to this object as RDF triples.

182 TRIPLES      21 PREDICATES      50 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00174169 schema:about N0209160b093942ee8ee46a3994326790
2 N0222bdb0f4ac4de88fe21f4fb46496e2
3 N04c614fec3b14b51a92bbf74ff5ad488
4 N19c584c342ad410a86a57d2284428620
5 N208caa79b80d40fbaa28e5731a5bcbab
6 N3237e4a575ce4d5196f80efdbab7b24a
7 N43e2c143e0c54cca8c943c630c75f4ae
8 N4cc113a87ef848b695ae6462c4bb847f
9 N4e5302d65bc644e29f0498c078d59987
10 N71525764d01a44688c4fef0a7657004f
11 N768b9b88c88f488c828da0229d6e83c9
12 N7c2d0648f8e74c19b7cca4a937606b82
13 N97a415bfea014a69848943b0e268b0e1
14 Nda337b971be34f0297e541cdc4ca9076
15 Ne87d492604cd4d3ab8f0cbc5b5d73f3f
16 Nf3e43cb6dde042e69347fefe25916c3e
17 anzsrc-for:11
18 anzsrc-for:1102
19 schema:author N59d3e93a8c694423be6e4b546de32545
20 schema:citation https://app.dimensions.ai/details/publication/pub.1080245438
21 https://app.dimensions.ai/details/publication/pub.1080245575
22 https://app.dimensions.ai/details/publication/pub.1082219497
23 https://doi.org/10.1021/jm00201a012
24 https://doi.org/10.1056/nejm197902083000603
25 schema:datePublished 1985-06
26 schema:datePublishedReg 1985-06-01
27 schema:description Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy. All the children had leukemia which was resistant to conventional therapy and all but one patient had received anthracycline therapy prior to the initiation of this trial. Three patients (two with ANLL, one with ALL) received the drug at a dose of 6 mg/m2/day i.v. for 5 days. Both patients with ANLL achieved partial remissions (PR) (105 and 87 days duration). The child with ALL failed to respond to two courses of the drug, and died of progressive disease 45 days after the institution of therapy. Twenty-one patients (14 with ALL, seven with ANLL) were treated with 8 mg/m2/day i.v. mitoxantrone for 5 days. There were three early deaths (all ALL) which were not felt to be secondary to drug toxicity. Four of the 18 children achieved complete remission (CR) (one ANLL - 35 days; three ALL - 39, 31 and 13 days). One child with ANLL achieved a PR (13 days) and one child with ALL showed improvement in his bone marrow status. Twelve children failed to respond to this therapy. Dose-limiting toxicity was not seen among the patients who received 6 mg/m2/day for 5 days. There were five patients who had mucositis and one patient who had nausea and vomiting among those patients who received 8 mg/m2/day for 5 days.(ABSTRACT TRUNCATED AT 250 WORDS)
28 schema:genre research_article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf N5ffd37aa1a0643798a94b9cbd63f779b
32 Ne0c4a71219344900b324303f502347d9
33 sg:journal.1094201
34 schema:name Mitoxantrone in refractory acute leukemia in children: A phase I study
35 schema:pagination 191-195
36 schema:productId N9ec56c40df2f4b7bb8b64d84021a02a8
37 Nde80beb1eb01429298a75b9dc1a7fdf2
38 Ndef991ab786d4509b86a48858deb007a
39 Neab56081fc39499ebcbf0c40c37dcd11
40 Nf515061b8105404bb33e314ee71027a9
41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015026290
42 https://doi.org/10.1007/bf00174169
43 schema:sdDatePublished 2019-04-15T08:49
44 schema:sdLicense https://scigraph.springernature.com/explorer/license/
45 schema:sdPublisher Na4767204d7ca40c592bc66a80e8895e2
46 schema:url http://link.springer.com/10.1007/BF00174169
47 sgo:license sg:explorer/license/
48 sgo:sdDataset articles
49 rdf:type schema:ScholarlyArticle
50 N0209160b093942ee8ee46a3994326790 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
51 schema:name Drug Evaluation
52 rdf:type schema:DefinedTerm
53 N0222bdb0f4ac4de88fe21f4fb46496e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
54 schema:name Adolescent
55 rdf:type schema:DefinedTerm
56 N04c614fec3b14b51a92bbf74ff5ad488 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Acute Disease
58 rdf:type schema:DefinedTerm
59 N19c584c342ad410a86a57d2284428620 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Mitoxantrone
61 rdf:type schema:DefinedTerm
62 N208caa79b80d40fbaa28e5731a5bcbab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Antineoplastic Agents
64 rdf:type schema:DefinedTerm
65 N3237e4a575ce4d5196f80efdbab7b24a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Alopecia
67 rdf:type schema:DefinedTerm
68 N36de07627e164ad798e95de3944c02be rdf:first sg:person.01103137043.20
69 rdf:rest rdf:nil
70 N43e2c143e0c54cca8c943c630c75f4ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Humans
72 rdf:type schema:DefinedTerm
73 N4cc113a87ef848b695ae6462c4bb847f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Heart
75 rdf:type schema:DefinedTerm
76 N4e5302d65bc644e29f0498c078d59987 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Leukemia
78 rdf:type schema:DefinedTerm
79 N4e9a51657c984e33993fdebb96ae51a9 rdf:first sg:person.01035023643.65
80 rdf:rest N36de07627e164ad798e95de3944c02be
81 N59d3e93a8c694423be6e4b546de32545 rdf:first sg:person.065570553.31
82 rdf:rest N9d876e8cd16442068e12ccd6249d5427
83 N5ffd37aa1a0643798a94b9cbd63f779b schema:issueNumber 2
84 rdf:type schema:PublicationIssue
85 N71525764d01a44688c4fef0a7657004f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Child
87 rdf:type schema:DefinedTerm
88 N768b9b88c88f488c828da0229d6e83c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Anthraquinones
90 rdf:type schema:DefinedTerm
91 N7c2d0648f8e74c19b7cca4a937606b82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Child, Preschool
93 rdf:type schema:DefinedTerm
94 N97a415bfea014a69848943b0e268b0e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Gastric Mucosa
96 rdf:type schema:DefinedTerm
97 N9d876e8cd16442068e12ccd6249d5427 rdf:first sg:person.01361214160.77
98 rdf:rest Ne1aace6d307d4f84a15dca163ce87ba2
99 N9ec56c40df2f4b7bb8b64d84021a02a8 schema:name doi
100 schema:value 10.1007/bf00174169
101 rdf:type schema:PropertyValue
102 Na4767204d7ca40c592bc66a80e8895e2 schema:name Springer Nature - SN SciGraph project
103 rdf:type schema:Organization
104 Nda337b971be34f0297e541cdc4ca9076 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Female
106 rdf:type schema:DefinedTerm
107 Nde80beb1eb01429298a75b9dc1a7fdf2 schema:name nlm_unique_id
108 schema:value 8309330
109 rdf:type schema:PropertyValue
110 Ndef991ab786d4509b86a48858deb007a schema:name pubmed_id
111 schema:value 4019122
112 rdf:type schema:PropertyValue
113 Ne0c4a71219344900b324303f502347d9 schema:volumeNumber 3
114 rdf:type schema:PublicationVolume
115 Ne1aace6d307d4f84a15dca163ce87ba2 rdf:first sg:person.014175614647.19
116 rdf:rest N4e9a51657c984e33993fdebb96ae51a9
117 Ne87d492604cd4d3ab8f0cbc5b5d73f3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Infant
119 rdf:type schema:DefinedTerm
120 Neab56081fc39499ebcbf0c40c37dcd11 schema:name dimensions_id
121 schema:value pub.1015026290
122 rdf:type schema:PropertyValue
123 Nf3e43cb6dde042e69347fefe25916c3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Male
125 rdf:type schema:DefinedTerm
126 Nf515061b8105404bb33e314ee71027a9 schema:name readcube_id
127 schema:value 4796eea39032581385da631fbc2be1b7673226be3b9606094c47202acc3ef7ba
128 rdf:type schema:PropertyValue
129 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
130 schema:name Medical and Health Sciences
131 rdf:type schema:DefinedTerm
132 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
133 schema:name Cardiorespiratory Medicine and Haematology
134 rdf:type schema:DefinedTerm
135 sg:journal.1094201 schema:issn 0167-6997
136 1573-0646
137 schema:name Investigational New Drugs
138 rdf:type schema:Periodical
139 sg:person.01035023643.65 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
140 schema:familyName Schoch
141 schema:givenName Ingrid
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035023643.65
143 rdf:type schema:Person
144 sg:person.01103137043.20 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
145 schema:familyName Dukart
146 schema:givenName Gary
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103137043.20
148 rdf:type schema:Person
149 sg:person.01361214160.77 schema:affiliation https://www.grid.ac/institutes/grid.240344.5
150 schema:familyName Mulne
151 schema:givenName Arlynn Faye
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361214160.77
153 rdf:type schema:Person
154 sg:person.014175614647.19 schema:affiliation https://www.grid.ac/institutes/grid.412016.0
155 schema:familyName Vats
156 schema:givenName Tribhawan S.
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014175614647.19
158 rdf:type schema:Person
159 sg:person.065570553.31 schema:affiliation https://www.grid.ac/institutes/grid.416975.8
160 schema:familyName Starling
161 schema:givenName Kenneth A.
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.065570553.31
163 rdf:type schema:Person
164 https://app.dimensions.ai/details/publication/pub.1080245438 schema:CreativeWork
165 https://app.dimensions.ai/details/publication/pub.1080245575 schema:CreativeWork
166 https://app.dimensions.ai/details/publication/pub.1082219497 schema:CreativeWork
167 https://doi.org/10.1021/jm00201a012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055938574
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1056/nejm197902083000603 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045207745
170 rdf:type schema:CreativeWork
171 https://www.grid.ac/institutes/grid.240344.5 schema:alternateName Nationwide Children's Hospital
172 schema:name Columbus Children's Hospital, Columbus, OH, U.S.A.
173 rdf:type schema:Organization
174 https://www.grid.ac/institutes/grid.410513.2 schema:alternateName Pfizer (United States)
175 schema:name Medical Research Division, Lederle Laboratories, American Cyanamid Company, Pearl River, NY, U.S.A.
176 rdf:type schema:Organization
177 https://www.grid.ac/institutes/grid.412016.0 schema:alternateName University of Kansas Medical Center
178 schema:name University of Kansas Medical Center, U.S.A.
179 rdf:type schema:Organization
180 https://www.grid.ac/institutes/grid.416975.8 schema:alternateName Texas Children's Hospital
181 schema:name Hematology-Oncology Section, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, TX, U.S.A.
182 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...